Cancer presents significant challenges owing to its complex molecular pathways and resistance to therapy. Natural metabolites have significant medicinal potential by regulating the sensing and signaling pathways associated with cancer development. Recognizing their interactions within the tumor microenvironment may unveil innovative techniques for inhibiting malignant activities and improve therapy success. This article highlights studies regarding ovarian cancer metabolism, signaling mechanisms, and therapeutic natural substances. This study summarizes clinical and experimental results to emphasise the synergistic effects of alkaloids, flavonoids, and terpenoids in improving therapeutic effectiveness and alleviating drug resistance. Bioactive compounds are essential in regulating ovarian cancer metabolism and signaling pathways, affecting glycolysis, lipid metabolism, and the survival of tumor cells. This review examines metabolic programming and essential pathways, including glycolysis, TCA cycle, lipid metabolism, PI3K/AKT/mTOR, AMPK, and MAPK, emphasizing their therapeutic significance. The integration of metabolic treatments with medicines based on natural compounds has significant potential for enhancing treatment effectiveness and mitigating therapeutic resistance. Ovarian cancer needs an integrated strategy that includes metabolic reprogramming, signaling modulation, and drugs derived from natural products. Natural chemicals provide intriguing approaches to address chemotherapy resistance and improve treatment efficacy. Further research is required to enhance these methodologies and evaluate their practical applicability for improved patient outcomes.
We examined factors associated with severe psychosocial maladaptation in adults with epilepsy and described profiles relevant to personalized rehabilitation. This observational study included 480 adults aged 25-45 years assessed in clinical rehabilitation settings during 2018-2026. Neurological, psychiatric, cognitive, and psychosocial characteristics were evaluated. Multivariable logistic regression estimated adjusted odds ratios (ORs) and 95% confidence intervals (CIs). Discrimination was evaluated using the area under the receiver operating characteristic curve (AUC). Anxiety symptoms occurred in 59.2%, depressive symptoms in 55.4%, cognitive impairment in 60.8%, and sleep disturbance in 65.0%. Severe maladaptation affected 263 participants (54.8%). Stigma-related distress had the largest adjusted OR (2.67; 95% CI, 1.78-4.01). Depressive symptoms, low adherence, anxiety symptoms, cognitive impairment, sleep disturbance, and drug-resistant epilepsy also retained associations with the outcome. The AUC was 0.82 (95% CI, 0.78-0.86), with a bootstrap-corrected AUC of 0.80. Five predominant rehabilitation profiles were identified. Multidimensional assessment may help identify individual rehabilitation priorities. The observational associations do not establish causality or intervention effectiveness. Calibration and external validation are required before individual clinical use of the model.